Cargando…

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

This phase II study evaluates the efficacy and toxicity of a prolonged schedule of oral etoposide in patients with measurable advanced ovarian cancer resistant to, or relapsed following, platinum-based chemotherapy. Forty-seven patients participated, 20 of whom had received more than one prior treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seymour, M. T., Mansi, J. L., Gallagher, C. J., Gore, M. E., Harper, P. G., Evans, T. R., Edmonds, P. M., Slevin, M. L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968773/ https://www.ncbi.nlm.nih.gov/pubmed/8286205

Ejemplares similares

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.
por: Harvey, V. J., et al.
Publicado: (1985)

Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
por: Huang, Qi, et al.
Publicado: (2020)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
por: Cowie, F. J., et al.
Publicado: (1995)

Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
por: Nakka, Thejeswar, et al.
Publicado: (2022)

Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.
por: Gore, M. E., et al.
Publicado: (1997)

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer
por: Baur, M, et al.
Publicado: (2005)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.
por: Lee, C. R., et al.
Publicado: (1993)

Does protracted chemotherapy have an influence on the clinical outcomes in advanced epithelial ovarian cancer?
por: Lee, Juhun, et al.
Publicado: (2022)

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.
por: Gogas, H., et al.
Publicado: (1997)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY
por: Garcia-Sanz, R., et al.
Publicado: (2022)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms
por: Lacombe, Caroline, et al.
Publicado: (2021)

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
por: Guan, Yelan, et al.
Publicado: (2023)

Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
por: Colombo, Nicoletta
Publicado: (2014)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
por: Seymour, L. K., et al.
Publicado: (1994)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse
por: Im, Annie, et al.
Publicado: (2016)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2020)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
por: Raja, F A, et al.
Publicado: (2011)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Case of Protracted Pregnancy
por: Kelly, A. L.
Publicado: (1870)

Case of Protracted Labor
por: Harcourt, L. A.
Publicado: (1871)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_675kpta7ojnu0ukplf8slr5cb1